Trial · NCT02697916
Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term
NCT02697916, Not applicable, Completed, Duke University; results first posted 2021-07-01
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term. Trials, record NCT02697916. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02697916
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term
- NCT number
- NCT02697916
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 15,076 participants, actual
- Lead sponsor
- Duke University
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- aspirin
- First posted
- 2016-03-03
- Last updated
- 2021-07-01
- Results first posted
- 2021-07-01
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Experiencing All-cause Death, Hospitalization for Nonfatal MI, or Hospitalization for Nonfatal Stroke in High-risk Patients With a History of MI or Documented Atherosclerotic Cardiovascular Disease (ASCVD) | Time of randomization through study completion, approximately 4 years | |
| Secondary | Number of Participants Experiencing All-cause Death | Time of randomization through study completion, approximately 4 years | |
| Secondary | Number of Participants Experiencing Hospitalization for Nonfatal MI | Time of randomization through study completion, approximately 4 years | |
| Secondary | Number of Participants Experiencing Hospitalization for Nonfatal Stroke | Time of randomization through study completion, approximately 4 years | |
| Secondary | Number of Participants Requiring Coronary Revascularization Procedures (Percutaneous Coronary Intervention [PCI] or Coronary Artery Bypass Grafting [CABG]) | Time of randomization through study completion, approximately 4 years | |
| Secondary | Quality of Life and Functional Status, as Measured on a 5-point Scale | 2 years | Quality of life measures are based on an ordinal scale from 1-5, where 1 corresponds to the best outcome and 5 to the worst. Model-based mean score estimates are obtained from mixed models of each quality of life measure. |
| Other | Number of Participants Experiencing Hospitalization for Major Bleeding Complications With an Associated Blood Product Transfusion | Time of randomization through study completion, approximately 4 years |
Source ClinicalTrials.gov
Outcomes7
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants Experiencing All-cause Death, Hospitalization for Nonfatal MI, or Hospitalization for Nonfatal Stroke in High-risk Patients With a History of MI or Documented Atherosclerotic Cardiovascular Disease (ASCVD) | Time of randomization through study completion, approximately 4 years | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants Experiencing All-cause Death | Time of randomization through study completion, approximately 4 years | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants Experiencing Hospitalization for Nonfatal MI | Time of randomization through study completion, approximately 4 years | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants Experiencing Hospitalization for Nonfatal Stroke | Time of randomization through study completion, approximately 4 years | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants Requiring Coronary Revascularization Procedures (Percutaneous Coronary Intervention [PCI] or Coronary Artery Bypass Grafting [CABG]) | Time of randomization through study completion, approximately 4 years | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Quality of Life and Functional Status, as Measured on a 5-point Scale | 2 years | score on a scale | MEAN | |
| OTHER_PRE_SPECIFIED | Number of Participants Experiencing Hospitalization for Major Bleeding Complications With an Associated Blood Product Transfusion | Time of randomization through study completion, approximately 4 years | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Number of Participants Experiencing All-cause Death, Hospitalization for Nonfatal MI, or Hospitalization for Nonfatal Stroke in High-risk Patients With a History of MI or Documented Atherosclerotic Cardiovascular Disease (ASCVD) | ASA 81mg | 590 | Participants | ||
Number of Participants Experiencing All-cause Death, Hospitalization for Nonfatal MI, or Hospitalization for Nonfatal Stroke in High-risk Patients With a History of MI or Documented Atherosclerotic Cardiovascular Disease (ASCVD) | ASA 325mg | 569 | Participants | ||
| Number of Participants Experiencing All-cause Death | ASA 81mg | 315 | Participants | ||
| Number of Participants Experiencing All-cause Death | ASA 325mg | 357 | Participants | ||
| Number of Participants Experiencing Hospitalization for Nonfatal MI | ASA 81mg | 228 | Participants | ||
| Number of Participants Experiencing Hospitalization for Nonfatal MI | ASA 325mg | 213 | Participants | ||
| Number of Participants Experiencing Hospitalization for Nonfatal Stroke | ASA 81mg | 102 | Participants | ||
| Number of Participants Experiencing Hospitalization for Nonfatal Stroke | ASA 325mg | 92 | Participants | ||
| Number of Participants Requiring Coronary Revascularization Procedures (Percutaneous Coronary Intervention [PCI] or Coronary Artery Bypass Grafting [CABG]) | ASA 81mg | 471 | Participants | ||
| Number of Participants Requiring Coronary Revascularization Procedures (Percutaneous Coronary Intervention [PCI] or Coronary Artery Bypass Grafting [CABG]) | ASA 325mg | 446 | Participants |
1 to 10 of 26Source ClinicalTrials.gov
See all 26 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | ASA 81mg | 7,540 | |
| Overall Study | STARTED | ASA 325mg | 7,536 | |
| Overall Study | COMPLETED | ASA 81mg | 6,962 | |
| Overall Study | COMPLETED | ASA 325mg | 6,828 | |
| Overall Study | NOT COMPLETED | ASA 81mg | 578 | |
| Overall Study | NOT COMPLETED | ASA 325mg | 708 |
Source ClinicalTrials.gov
Adverse events10
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | PCI or CABG | Cardiac disorders | ASA 81mg | 471 | 7,434 | 471 |
| other | PCI or CABG | Cardiac disorders | ASA 325mg | 446 | 7,330 | 446 |
| other | Transient ischemia attack (TIA) | Cardiac disorders | ASA 81mg | 20 | 7,434 | 20 |
| other | Transient ischemia attack (TIA) | Cardiac disorders | ASA 325mg | 25 | 7,330 | 25 |
| serious | Non-Fatal MI | Cardiac disorders | ASA 81mg | 228 | 7,434 | 228 |
| serious | Non-Fatal MI | Cardiac disorders | ASA 325mg | 213 | 7,330 | 213 |
| serious | Non-Fatal Stroke | Vascular disorders | ASA 81mg | 102 | 7,434 | 102 |
| serious | Non-Fatal Stroke | Vascular disorders | ASA 325mg | 92 | 7,330 | 92 |
| serious | Major Bleeding | Cardiac disorders | ASA 81mg | 53 | 7,434 | 53 |
| serious | Major Bleeding | Cardiac disorders | ASA 325mg | 44 | 7,330 | 44 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | ASA 81mg | 315 | 7,434 |
| Total, all-cause mortality | ASA 325mg | 357 | 7,330 |
| Total, other adverse events | ASA 81mg | 491 | 7,434 |
| Total, other adverse events | ASA 325mg | 471 | 7,330 |
| Total, serious adverse events | ASA 81mg | 383 | 7,434 |
| Total, serious adverse events | ASA 325mg | 349 | 7,330 |
Source ClinicalTrials.gov
Papers13
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons8
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| ASA 81mg vs ASA 325mg: Number of Participants Experiencing Hospitalization for Nonfatal MI | Trial comparisons |
| ASA 81mg vs ASA 325mg: Number of Participants Experiencing Hospitalization for Nonfatal Stroke | Trial comparisons |
| ASA 81mg vs ASA 325mg: Number of Participants Experiencing All-cause Death | Trial comparisons |
| ASA 81mg vs ASA 325mg: Number of Participants Experiencing Hospitalization for Major Bleeding Complications With an Associated Blood Product Transfusion | Trial comparisons |
| ASA 81mg vs ASA 325mg: deaths from any cause | Trial comparisons |
ASA 81mg vs ASA 325mg: Number of Participants Experiencing All-cause Death, Hospitalization for Nonfatal MI, or Hospitalization for Nonfatal Stroke in High-risk Patients With a History of MI or Documented Atherosclerotic Cardiovascular Disease (ASCVD) | Trial comparisons |
| ASA 81mg vs ASA 325mg: Number of Participants Requiring Coronary Revascularization Procedures (Percutaneous Coronary Intervention [PCI] or Coronary Artery Bypass Grafting [CABG]) | Trial comparisons |
| ASA 81mg vs ASA 325mg: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02697916
GET https://conductscience.org/api/trials/v1/NCT02697916/results?page=2